Emrusolmin

DRUG2 trials

Sponsors

Teva Branded Pharmaceutical Products R&D LLC

Conditions

Multiple System Atrophy

Phase 2

A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients with Multiple System Atrophy

RecruitingCTIS2023-505320-54-00

Teva Branded Pharmaceutical Products R&D LLCMultiple System Atrophy

Start: 2025-01-30Target: 103Updated: 2025-10-13

An Open-Label Extension, Multi-centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants with Multiple System Atrophy

Not yet recruitingCTIS2025-521642-14-00

Teva Branded Pharmaceutical Products R&D LLCMultiple System Atrophy

Target: 53Updated: 2026-02-04